Cat. No.: HY-100113

Buloxibutid

(Synonyms: AT2 receptor agonist C21)

5 Cited Publications

Avis client

Based on 5 publication(s) in Google Scholar

Buloxibutid (AT2 receptor agonist C21) is an orally active, selective angiotensin II type 2 receptor (AT2R) agonist, with a K_i value of 0.4 nM for porcine AT2R. Buloxibutid exerts effects such as vasodilation, anti-inflammation, anti-fibrosis (promoting the expression of collagenase MMP-13) and tissue repair mainly by activating the NO/cGMP pathway, inhibiting the pro-proliferative MAPK signaling, and suppressing the pro-fibrotic TGF-β/Smad pathway as well as the inflammatory NF-κB pathway. Buloxibutid can be used in research related to idiopathic pulmonary fibrosis, hypertension, and systemic sclerosis.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 98.94%
CAS No.: 477775-14-7
Formule: C₂₃H₂₉N₃O₄S₂
Masse moléculaire:475.62

Stockage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Buloxibutid Chemical Structure

CAS No.: 477775-14-7

Size

Prix

Stock

Quantité

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (5)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Bioz

Activité biologique

Description

IC₅₀ & Target^[4]

AT2 Receptor

0.4 nM (Ki)

AT1 Receptor

> 10 μM (Ki)

Voir tous les produits spécifiques à Isoform Angiotensin Receptor :

Voir tous les produits spécifiques à Isoform p38 MAPK :

Voir tous les produits spécifiques à Isoform TGF-beta/Smad :

Smad1
Smad3

Voir tous les produits spécifiques à Isoform TGF-β Receptor :

Voir tous les produits spécifiques à Isoform MMP :

In Vitro

Buloxibutid (1-10 μM) inhibits the expression and signaling of proinflammatory pathways in LPS (HY-D1056)-induced THP-1 macrophages in a time- and concentration-dependent manner at concentrations of 1 and 10 μM^[2].
Buloxibutid (Compound 21) (0.1-0.1 μM; 3 days) induces neurite outgrowth in NG108-15 cells by activating AT₂ receptors. After treatment with 0.1 μM for 3 days, it increases the proportion of neurite-positive cells to 19.9%, and its signal transduction depends on the MAPK, cGMP and cGMP-dependent protein kinase pathways^[4].
Buloxibutid (100 nM; 0-1 h) transiently activates p42/p44mapk in NG108-15 cells via activation of the AT₂ receptor, and its phosphorylation level increases by 2.2-fold after treatment with 0.1 μM for 30 min^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Differentiation Assay^[4]

Cell Line:

NG108-15 neuroblastoma-glioma hybrid cells
Concentration:

0.1 nM、1 nM、0.1 μM、1 μM
Incubation Time:

3 days
Result:

Increased the percentage of neurite-positive cells from 5.5% (control) to 19.9% at 0.1 μM treatment.
Induced neurite outgrowth at concentrations ≥ 0.1 nM.
Had its neurite outgrowth effect abolished by co-incubation with PD 123,319.
Had its neurite outgrowth effect reduced by co-incubation with PD 98,059, LY-83,583, or KT 5823.

Western Blot Analysis^[4]

Cell Line:

NG108-15 neuroblastoma-glioma hybrid cells
Concentration:

100 nM
Incubation Time:

0, 30 and 60 min
Result:

Induced a 2.2-fold increase in phosphorylated p42/p44mapk levels relative to control within 30 min.
Decreased phosphorylated p42/p44mapk levels to basal levels by 60 min.
Had its 30-min activation abolished by pre-incubation with PD 123,319.

In Vivo

Buloxibutid (0.03 mg/kg/day; i.p.; daily administration; for 2 consecutive weeks) prevents and reverses bleomycin (HY-108345)-induced pulmonary fibrosis, vascular remodeling and inflammatory responses in Sprague-Dawley rats^[2].
Buloxibutid (0.3 mg/kg/day; mini pump; daily administration; for 7 consecutive days) alleviates bleomycin-induced pulmonary fibrosis in rats^[2].
Buloxibutid (1 mg/kg; i.p.; single administration) attenuates lung injury and inflammation induced by ventilator-induced lung injury (VILI) in Sprague-Dawley rats^[2].
Buloxibutid (0.3 mg/kg/day; i.p.; daily) alleviates LPS-induced acute lung injury in C57Bl/6 mice^[2].
Buloxibutid (0.3 mg/kg/day; i.p.; daily administration) alleviates hyperoxia-induced acute lung injury in C57Bl/6 mice^[2].
Buloxibutid (0.1-1 mg/kg/day; i.p.; administered daily for 7 consecutive days) reduces acute cigarette smoke-induced inflammation in female BALB/c mice, with the maximum efficacy observed at a dose of 0.3 mg/kg/day^[2].
Buloxibutid (0.3 mg/kg/day; i.p.; daily administration; for 3 consecutive weeks) reduces chronic cigarette smoke-induced inflammation, epithelial injury and profibrotic responses, while improving pulmonary function in BALB/c mice^[2].
Buloxibutid (0.03 mg/kg/day; i.p.; daily administration for 2 consecutive weeks) reverses monocrotaline-induced pulmonary fibrosis and myocardial fibrosis in male Sprague-Dawley rats^[2].
Buloxibutid (0.03 mg/kg; i.p.; once daily; for 14 consecutive days) significantly reduces systolic blood pressure, diastolic blood pressure, and mean blood pressure by 34.4%, 40.2%, and 38.0%, respectively, in male Sprague Dawley rats with hypertension induced by L-NAME/NaCl. It also improves the antioxidant status of the heart and aorta, alleviates histopathological damage to cardiac tissue, and restores normal aortic structure^[3].
Buloxibutid (0.03 mg/kg; i.p.; daily; 14 days) combined with Empagliflozin (HY-15409) significantly improves the antioxidant status of the heart and aorta in male Sprague Dawley rats with hypertension induced by L-NAME/NaCl, reduces aortic MDA levels by 27.5%, restores normal aortic structure, alleviates cardiac histopathological damage, and exerts a synergistic effect on aortic SOD and CAT activities^[3].
Buloxibutid (Compound 21) (0.003-0.3 mg/kg/h; i.v.; continuous infusion; 100 μM; intraluminal perfusion) dose-dependently enhances duodenal mucosal alkaline secretion in male Sprague-Dawley rats via activation of the AT2 receptor, with the maximal effect observed at an intravenous dose of 0.3 mg/kg/h^[4].
Buloxibutid (0.008-4 mg/kg; i.v.; single bolus) induces a significant AT2 receptor-mediated reduction in mean arterial pressure at intravenous doses of 0.008 mg/kg and 0.05 mg/kg in anesthetized spontaneously hypertensive rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley (bleomycin-induced pulmonary fibrosis)^[2]
Dosage:

0.03 mg/kg/day
Administration:

i.p.; daily; 2 weeks
Result:

Attenuated bleomycin-induced increases in right ventricular systolic pressure (RVSP).
Reduced cardiac and pulmonary vascular remodeling.
Caused significant reductions in % fibrotic area, Ashcroft scoring, and hydroxyproline content.
Prevented or reversed bleomycin-induced increases in Col1a/3a1, CTGF, MMP-12, TIMP-1, and IL-13 gene expression to baseline levels.
Mitigated inflammatory responses, reducing pro-inflammatory gene expression (CCL2, IL-6, TLR4) and infiltration of CD68+ macrophages.
Reduced bleomycin-induced increases in AT₂R gene expression.

Animal Model:

Sprague-Dawley (bleomycin-induced pulmonary fibrosis)^[2]
Dosage:

0.3 mg/kg/day
Administration:

minipump; daily; 7 days
Result:

Reduced bleomycin-induced increases in Ashcroft score and % interstitial collagen area, with slightly greater efficacy than β-Pro⁷ Ang III.
Exhibited higher efficacy than pirfenidone at reducing these fibrotic measures.
Reduced lung myofibroblast accumulation and TGFβ expression to a similar extent as β-Pro⁷ Ang III and pirfenidone.
Tended to increase lung compliance relative to the bleomycin group.

Animal Model:

Sprague-Dawley (ventilation-induced lung injury)^[2]
Dosage:

1 mg/kg
Administration:

i.p.; single dose
Result:

Significantly attenuated VILI-induced lung damage.
Reduced cell and protein content in BALF.
Caused a significant increase in the anti-inflammatory cytokines IL-4 and IL-10.

Animal Model:

BALB/c (female; acute cigarette smoke-induced chronic obstructive pulmonary disease)^[2]
Dosage:

0.1 mg/kg/day; 0.3 mg/kg/day; 1 mg/kg/day
Administration:

i.p.; daily; 7 days
Result:

Exhibited dose-dependent anti-inflammatory effects, with reduced cytokines and cells in BAL fluid; maximal effects were seen with the 0.3 mg/kg dose.
Restored alveolar macrophage phagocytic ability at 0.3 mg/kg/day.
Suppressed cigarette smoke-induced pro-inflammatory marker expression at 0.3 mg/kg/day.
Restored M2-phenotypic marker expression at 0.3 mg/kg/day.
Upregulated AT₂R and MasR expression at 0.3 mg/kg/day.
Reversed cigarette smoke-induced reductions in AT₂R expression.

Animal Model:

BALB/c (chronic cigarette smoke-induced chronic obstructive pulmonary disease)^[2]
Dosage:

0.3 mg/kg/day
Administration:

i.p.; daily; 3 weeks
Result:

Significantly reduced cigarette smoke-induced increases in pro-inflammatory cytokines and alveolar epithelial thickening.
Opposed cigarette smoke-induced pro-fibrotic responses, reducing active TGFβ1, SMAD2/3, hydroxyproline, MMP-9, and MMP-12 levels; augmented cigarette smoke-induced increase in TIMP-1.
Elicited significant protective effects in all measured lung function parameters.
Reversed cigarette smoke-induced increases in AT₂R expression toward baseline.

Animal Model:

Sprague-Dawley (male; monocrotaline-induced pulmonary hypertension with interstitial fibrosis)^[2]
Dosage:

0.03 mg/kg/day
Administration:

i.p.; daily; 2 weeks
Result:

Reversed lung interstitial and peri-vascular fibrosis, as well as cardiac fibrosis; this anti-fibrotic effect was abrogated by co-administration of an AT₂R antagonist or MasR antagonist.
Reversed monocrotaline-induced increases in ACE gene expression and decreases in ACE2 gene expression, increasing ACE2 to double control levels.
Significantly increased AT₂R gene expression relative to monocrotaline-treated and control rats.

Animal Model:

Sprague Dawley (male, hypertension induced via 40 mg/kg L-NAME i.p. daily for 28 days plus 1% NaCl in drinking water for 28 days)^[3]
Dosage:

0.03 mg/kg
Administration:

i.p.; once daily; 14 days
Result:

Reduced median systolic blood pressure to 73.77 mmHg.
Reduced median diastolic blood pressure to 57.82 mmHg.
Reduced median mean blood pressure to 67.465 mmHg.
Reduced median heart rate to 215.075 beats/min.
Reduced median heart weight to 1.177 g.
Increased median superoxide dismutase (SOD) activity to 6.303 U/g protein.
Increased median glutathione peroxidase (GPx) activity to 79.698 U/mg protein.
Increased median glutathione (GSH) level to 51.333 μmol/g tissue.
Increased median aortic SOD activity to 16.511 U/g protein.
Increased median catalase (CAT) activity to 42.085 K/g protein.
Increased median aortic GPx activity to 104.833 U/mg protein.
Increased median calcium level to 9.95 mg/dL.
Reduced median total cholesterol to 38.5 mg/dL.
Reduced median histopathological damage scores for degenerated cardiomyocytes, hemorrhage, inflammatory infiltration, and collagen deposition to 0.
Restored thoracic aorta sections to normal histological structure, similar to control group, with no dilatation or irregularities in elastic lamellae.

Animal Model:

Sprague Dawley (male, hypertension induced via 40 mg/kg L-NAME i.p. daily for 28 days plus 1% NaCl in drinking water for 28 days)^[3]
Dosage:

0.03 mg/kg (buloxibutid); 7 mg/kg (empagliflozin)
Administration:

i.p. (buloxibutid; once daily; 14 days); p.o. (Empagliflozin; once daily; 14 days)
Result:

Increased median heart rate to 298.69 beats/min.
Increased median cardiac SOD activity to 6.476 U/g protein.
Increased median cardiac GPx activity to 82.782 U/mg protein.
Reduced median total oxidant level (TOS) to 4.01 μmol/L.
Reduced median malondialdehyde (MDA) level to 55.23 nmol/g tissue.
Increased median aortic GSH level to 50.264 μmol/g tissue.
Increased median aortic SOD activity to 18.059 U/g protein.
Increased median aortic CAT activity to 63.554 K/g protein.
Increased median aortic GPx activity to 110.402 U/mg protein.
Increased median calcium level to 10 mg/dL.
Increased median total cholesterol to 46 mg/dL.
Increased median low-density lipoprotein (LDL) cholesterol to 15 mg/dL.
Reduced median chlorine level to 101 mmol/L.
Reduced median sodium level to 138 mmol/L.
Reduced median histopathological damage scores for degenerated cardiomyocytes, hemorrhage, inflammatory infiltration, with residual inflammatory cell infiltration observed.
Restored thoracic aorta sections to normal histological structure, similar to control group, with no dilatation or irregularities in elastic lamellae.

Animal Model:

Sprague-Dawley (male, nonfasted, surgically isolated duodenal segments)^[4]
Dosage:

0.003-0.3 mg/kg/h; 100 μM
Administration:

i.v.; continuous infusion; intraluminal perfusion
Result:

Increased duodenal mucosal alkaline secretion in a dose-dependent manner: 0.003 mg/kg/h induced a small secretion increase, 0.03 mg/kg/h induced a moderate increase, and 0.3 mg/kg/h induced the largest increase (mean change from baseline ~47%).
Increased alkaline secretion by mean change from baseline ~30% at 100 μM intraluminal administration.
Produced secretory responses that were significantly inhibited by co-administration of the AT2 receptor antagonist PD 123,319.

Animal Model:

Spontaneously hypertensive (SHR, male, anesthetized)^[4]
Dosage:

0.008 mg/kg; 0.05 mg/kg; 4 mg/kg
Administration:

i.v.; single bolus
Result:

Reduced mean arterial pressure by a mean of ~25 mmHg within 30 minutes at 0.05 mg/kg i.v., and this effect was attenuated by co-administration of PD 123,319.
Decreased mean arterial pressure at low-dose 0.008 mg/kg.
Did not produce a statistically significant change in mean arterial pressure compared to vehicle at higher dose 4 mg/kg.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 477775-14-7
Appearance Solid
Masse moléculaire 475.62
Formule C₂₃H₂₉N₃O₄S₂
Color White to yellow
SMILES

O=C(OCCCC)NS(=O)(C1=C(C2=CC=C(CN3C=CN=C3)C=C2)C=C(CC(C)C)S1)=O
Synonyms

AT2 receptor agonist C21
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (5)

All

Sort by:

Journal Impact Factor

Acta Pharmacol Sin

Angiotensin II type-2 receptor signaling facilitates liver injury repair and regeneration via inactivation of Hippo pathway. [Abstract]

2024 Jun;45(6):1201-1213. PMID: 38491160
Clin Sci

G-protein-coupled receptor kinase 4 causes renal angiotensin II type 2 receptor dysfunction by increasing its phosphorylation. [Abstract]

2022 Jun 30;136(12):989-1003. PMID: 35695067
Cell Mol Life Sci

Involvement of miRNA-204 carried by the exosomes of macrophages in the AT2 receptor-mediated improvement of vascular calcification. [Abstract]

2025 Apr 18;82(1):165. PMID: 40249512
Eur J Pharmacol

Activation of angiotensin II type 2 receptor attenuates lung injury of collagen-induced arthritis by alleviating endothelial cell injury and promoting Ly6Clo monocyte transition. [Abstract]

2023 Feb 15:941:175466. PMID: 36528072
Dokkyo Medical Journal

2023 Sep 8.

Solvant et solubilité

In Vitro:

DMSO : 50 mg/mL (105.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1025 mL

10.5126 mL

21.0252 mL

5 mM

0.4205 mL

2.1025 mL

4.2050 mL

10 mM

0.2103 mL

1.0513 mL

2.1025 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (298 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Rein-Hedin E, et al. Utilizing venous occlusion plethysmography to assess vascular effects: A study with buloxibutid, an angiotensin II type 2 receptor agonist. Clin Transl Sci. 2024;17(2):e13735. [Content Brief]

[2]. Young ON, et al. Investigational insights into the potential of angiotensin type II receptor agonists as therapeutics for idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. 2026;35(1):63-73. [Content Brief]

[3]. Ozhan O, et al. Protective effects of buloxibutid and empagliflozin on hypertension-induced cardiac and vascular injury in rats. J Mol Histol. 2026;57(1):35. Published 2026 Jan 10. [Content Brief]

[4]. Wan Y, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47(24):5995-6008. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1025 mL	10.5126 mL	21.0252 mL	52.5630 mL
	5 mM	0.4205 mL	2.1025 mL	4.2050 mL	10.5126 mL
	10 mM	0.2103 mL	1.0513 mL	2.1025 mL	5.2563 mL
	15 mM	0.1402 mL	0.7008 mL	1.4017 mL	3.5042 mL
	20 mM	0.1051 mL	0.5256 mL	1.0513 mL	2.6281 mL
	25 mM	0.0841 mL	0.4205 mL	0.8410 mL	2.1025 mL
	30 mM	0.0701 mL	0.3504 mL	0.7008 mL	1.7521 mL
	40 mM	0.0526 mL	0.2628 mL	0.5256 mL	1.3141 mL
	50 mM	0.0421 mL	0.2103 mL	0.4205 mL	1.0513 mL
	60 mM	0.0350 mL	0.1752 mL	0.3504 mL	0.8760 mL
	80 mM	0.0263 mL	0.1314 mL	0.2628 mL	0.6570 mL
	100 mM	0.0210 mL	0.1051 mL	0.2103 mL	0.5256 mL

Buloxibutid

5 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Buloxibutid

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Wnt/Hedgehog/Notch Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Antihypertensive Compound Library

Protease Inhibitor Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Buloxibutid

Voir tous les produits spécifiques à Isoform Angiotensin Receptor

Voir tous les produits spécifiques à Isoform p38 MAPK

Voir tous les produits spécifiques à Isoform TGF-beta/Smad

Voir tous les produits spécifiques à Isoform TGF-β Receptor

Voir tous les produits spécifiques à Isoform MMP

Activité biologique

Chemical Information

Publications (5)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Buloxibutid Related Classifications

Cat. No.: HY-100113